Stockscreener 앱 받기
1.89
3.08%
-0.06
시간 외 거래:
1.90
0.01
+0.53%
전일 마감가:
$1.95
열려 있는:
$1.98
하루 거래량:
192.54K
Relative Volume:
0.96
시가총액:
$55.89M
수익:
$80.97M
순이익/손실:
$-78.31M
주가수익비율:
-0.1705
EPS:
-11.0849
순현금흐름:
$-129.56M
1주 성능:
-3.57%
1개월 성능:
+6.18%
6개월 성능:
+1.61%
1년 성능:
-12.09%
1일 변동 폭
$1.88
$1.9961
1주일 범위
$1.88
$2.03
52주 변동 폭
$1.325
$2.89
Fortress Biotech Inc Stock (FBIO) Company Profile
명칭
Fortress Biotech Inc
전화
781-652-4500
주소
1111 KANE CONCOURSE, BAY HARBOR ISLANDS, NY
FBIO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
FBIO
Fortress Biotech Inc
|
1.89 | 57.96M | 80.97M | -78.31M | -129.56M | -11.08 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.49 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.53 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.52 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
566.14 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.93 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
Fortress Biotech Inc Stock (FBIO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-03-15 | 재개 | ROTH MKM | Buy |
| 2022-08-04 | 개시 | Ladenburg Thalmann | Buy |
| 2020-10-02 | 개시 | The Benchmark Company | Buy |
| 2019-12-18 | 개시 | B. Riley FBR | Buy |
| 2018-02-28 | 개시 | B. Riley FBR, Inc. | Buy |
| 2017-07-11 | 개시 | Rodman & Renshaw | Buy |
| 2017-03-22 | 개시 | JMP Securities | Mkt Outperform |
| 2016-10-03 | 개시 | ROTH Capital | Buy |
모두보기
Fortress Biotech Inc 주식(FBIO)의 최신 뉴스
What drives Fortress Biotech Inc. stock priceHigh-impact investment strategies - jammulinksnews.com
What analysts say about Fortress Biotech Inc. stockFree Stock Movement Tracking - jammulinksnews.com
Will Fortress Biotech Inc. stock split in the near futureVerified Return Tips - beatles.ru
Fortress Biotech Inc. Stock Analysis and ForecastFree Wealth Planning Blueprint - jammulinksnews.com
Is Fortress Biotech Inc. a good long term investmentExponentially increasing returns - jammulinksnews.com
AstraZeneca’s Anselamimab Trial Shows Mixed Results - TipRanks
Why Fortress Biotech Inc. stock attracts strong analyst attentionFree AI-Powered Stock Predictions - Newser
How Fortress Biotech Inc. stock performs during market volatilityShort Term Profit Focus - Newser
What makes Fortress Biotech Inc. stock price move sharplyMarket Ready Callouts - Newser
Why Fast-paced Mover Fortress Biotech (FBIO) Is a Great Choice for Value Investors - Yahoo Finance
Journey Medical Corporation Announces Expanded Payer Coverage for Emrosi™ - Stock Titan
Mustang Bio Granted Orphan Drug Designation by U.S. FDA for - GlobeNewswire
(FBIOP) Trading Advice - news.stocktradersdaily.com
Fortress Biotech, Inc.(NasdaqCM: FBIO) dropped from Russell 3000E Growth Index - MarketScreener
Journey Medical to Join Russell 2000® and Russell 3000® Indexes - GlobeNewswire
Fortress Biotech shareholders approve board proposals at annual meeting - Investing.com
Journey Medical Corporation Announces Emrosi™ Data Analysis - GlobeNewswire
Despite Fast-paced Momentum, Fortress Biotech (FBIO) Is Still a Bargain Stock - Nasdaq
How To Trade (FBIOP) - news.stocktradersdaily.com
Two Sigma Investments LP Invests $109,000 in Fortress Biotech, Inc. (NASDAQ:FBIO) - Defense World
Journey Medical Corporation Announces Emrosi™ Featured on “The Balancing Act” Airing on Lifetime TV - GlobeNewswire
Jane Street Group LLC Takes Position in Fortress Biotech, Inc. (NASDAQ:FBIO) - Defense World
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Fortress Biotech, Inc. of Class Action Lawsuit and Upcoming Deadline – FBIO - ACCESS Newswire
Fortress Biotech (FBIO) Is Attractively Priced Despite Fast-paced Momentum - Yahoo Finance
Checkpoint Therapeutics, Inc.(NasdaqCM: CKPT) dropped from S&P TMI Index - marketscreener.com
Fortress Biotech Announces Closing of Sale of Subsidiary Checkpo - GuruFocus
Fortress Biotech Announces Sale of Subsidiary Checkpoint Therapeutics - citybiz
Sun Pharmaceutical Industries Completes Acquisition Of Checkpoint Therapeutics - marketscreener.com
Fortress Biotech Closes Sale of Checkpoint Therapeutics Unit - marketscreener.com
Fortress Biotech Announces Closing of Sale of Subsidiary Checkpoint Therapeutics | FBIO Stock News - GuruFocus
Fortress Biotech Announces Closing of Sale of Subsidiary Checkpoint Therapeutics - GlobeNewswire
Fortress Biotech, Inc. Announces Acquisition of Checkpoint Therapeutics by Sun Pharmaceutical Industries Limited - Nasdaq
Fortress Biotech Announces Closing of Sale of Subsidiary Checkpoint Therapeutics - Benzinga
Fortress Biotech: Forging a Fortress Through Strategic Asset Realization and Portfolio Precision - AInvest
Checkpoint Therapeutics shareholders approve Sun Pharma merger By Investing.com - Investing.com India
One Fortress Biotech Insider Raised Stake By 26% In Previous Year - simplywall.st
Checkpoint Investor Sues for Info on Sale From Fortress to Sun - Bloomberg Law News
Checkpoint Pharma Sued Over Controversial $355M Merger - USA Herald
New Strong Sell Stocks for May 16th - The Globe and Mail
Q2 EPS Estimates for Fortress Biotech Raised by Roth Capital - Defense World
How the (FBIOP) price action is used to our Advantage - news.stocktradersdaily.com
Sun Pharma Q4 Consol Net PAT 21.5 Billion Rupees - marketscreener.com
Fortress Biotech Reports Q1 2025 Financial Highlights - TipRanks
Fortress Biotech First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Fortress Biotech Inc (FBIO) Reports Q1 2025 Revenue of $13.1M, S - GuruFocus
Fortress Biotech: Q1 Earnings Snapshot - CT Insider
New Strong Sell Stocks For May 16th - Barchart.com
Fortress Biotech Inc (FBIO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.87%
0.17%
자본화:
|
볼륨(24시간):